HC Wainwright Reiterates “Neutral” Rating for Bionomics (NASDAQ:BNOX)

Bionomics (NASDAQ:BNOX – Get Rating)‘s stock had its “neutral” rating restated by HC Wainwright in a report released on Thursday, Benzinga reports.

Other equities analysts have also recently issued research reports about the stock. Evercore ISI reiterated an “in-line” rating and issued a $6.00 target price (down previously from $17.00) on shares of Bionomics in a research report on Tuesday, December 20th. Loop Capital boosted their price objective on shares of Bionomics from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Thursday.

Bionomics Stock Performance

Shares of NASDAQ:BNOX opened at $3.43 on Thursday. The company’s fifty day moving average is $3.93 and its 200 day moving average is $6.17. Bionomics has a 52 week low of $2.49 and a 52 week high of $10.90.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Point72 Asset Management L.P. acquired a new position in Bionomics Limited (NASDAQ:BNOX – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 128,000 shares of the company’s stock, valued at approximately $595,000. Point72 Asset Management L.P. owned 1.57% of Bionomics at the end of the most recent reporting period. Institutional investors own 2.73% of the company’s stock.

Bionomics Company Profile

(Get Rating)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.